RVMD · NASDAQ
Revolution Medicines, Inc.
$186.00 -1.56 (-0.83%)
Company overview
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancers. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON).
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $39.9B
- Employees
- 616
- Headquarters
- Redwood City, CA
- Website
- revmed.com
- CEO
- Mark A. Goldsmith
- Listed
- February 13, 2020
- P/E
- -26.16
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$9.2M
- Operating income
- -$1.4B
- EBITDA
- -$1.3B
- Net income
- -$1.4B
- EPS
- -$7.11
- Total assets
- $2.3B
- Total debt
- $157M
- Earnings yield
- -3.82%
No geographic segmentation.
Showing FY 2022
RVMD
1D
NASDAQ
O192.06H194.59L185.34C187.69-6.59 (-3.39%)Vol1.49M